ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,917.11
0.00%
US Tech 100
20,112.40
-0.07%
Dow Jones
43,408.47
0.32%
Brent Oil
73.855
1.39%
Bitcoin
97,900.69
3.75%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Alzamend Neuro Inc (ALZN) Quote

Alzamend Neuro Inc

Alzamend Neuro Inc (ALZN)

NASDAQ
1.31
-0.09
(-6.43%)
Closed November 20 4:00PM
Delayed by 15 minutes
1.31
0.00
( 0.00% )
Pre Market: 4:01AM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
1.31
Bid
1.30
Ask
1.44
Volume
-
0.00 Day's Range 0.00
1.25 52 Week Range 15.06
Market Cap
5.096M
Previous Close
1.31
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
287,374
Shares Outstanding
3,890,064
Dividend Yield
-
PE Ratio
-0.51
Earnings Per Share (EPS)
-2.56
Revenue
-
Net Profit
-9.95M

About Alzamend Neuro Inc

Alzamend Neuro Inc is an early clinical stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipe... Alzamend Neuro Inc is an early clinical stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.alzamend.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Alzamend Neuro Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ALZN. The last closing price for Alzamend Neuro was $1.31. Over the last year, Alzamend Neuro shares have traded in a share price range of $ 1.25 to $ 15.06.

Alzamend Neuro currently has 3,890,064 shares outstanding. The market capitalization of Alzamend Neuro is $5.10 million. Alzamend Neuro has a price to earnings ratio (PE ratio) of -0.51.

Ask ADVFN Intelligence (AI)

ALZN Latest News

More News

Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice

Alzamend is developing AL001, a lithium product designed for enhanced safety and efficacy compared to currently available FDA-approved and marketed lithium therapies At a low dose, AL001...

November 19 2024
Business Wire

Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Data confirm the positive topline results announced in June 2023 identifying a maximum tolerated dose as assessed by an independent safety review committee Identified dose is unlikely to require...

October 16 2024
Business Wire

Form 8-K - Current report

October 15 2024
Edgar (US Regulatory)

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar...

October 15 2024
Business Wire

Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference

Fireside conversation to take place on October 17, 2024, at 1:30 PM ET Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel...

October 10 2024
Business Wire

Form 424B5 - Prospectus [Rule 424(b)(5)]

October 03 2024
Edgar (US Regulatory)

Form 8-K - Current report

October 03 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

September 11 2024
Edgar (US Regulatory)

Alzamend Neuro Issues Letter to Stockholders

Alzamend recently announced partnership with Massachusetts General Hospital for five phase II clinical trials of AL001, involving healthy human subjects and patients with Alzheimer’s, BD, MDD...

August 26 2024
Business Wire

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the study Head-to-head study of AL001 versus a marketed lithium carbonate product will...

August 19 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.13-9.027777777781.441.471.251487131.37149174CS
4-0.3299-20.11708030981.63991.691.251205841.48492236CS
12-1.07-44.95798319332.382.771.252873741.81423435CS
26-5.001-79.24259229926.31115.061.259136074.97512827CS
52-11.09-89.43548387112.415.061.255001805.27526936CS
156-327.19-99.601217656328.54741.25715679195.26733933CS
260-4348.69-99.969885057543505032.51.251154222370.50828285CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WORXSCWorx Corporation
$ 1.94
(97.96%)
13.79M
AKTSAkoustis Technologies Inc
$ 0.1503
(72.56%)
39.07M
PETWag Group Company
$ 0.32
(52.31%)
14.53M
CCECCapital Clean Energy Carriers Corporation
$ 24.99
(34.72%)
9
VEEAVeea Inc
$ 3.70
(31.21%)
3.18M
WSBFWaterstone Financial Inc
$ 9.00
(-40.98%)
4
TRSTriMas Corporation
$ 15.62
(-40.79%)
1
BCAXBicara Therapeutics Inc
$ 11.00
(-40.15%)
207
PYXSPyxis Oncology Inc
$ 2.37
(-37.96%)
170.71k
XNCRXencor Inc
$ 15.11
(-36.30%)
2
AKTSAkoustis Technologies Inc
$ 0.1503
(72.56%)
39.07M
PETWag Group Company
$ 0.32
(52.31%)
14.53M
WORXSCWorx Corporation
$ 1.94
(97.96%)
13.79M
XTKGX3 Holdings Company Ltd
$ 0.081
(-10.00%)
10.52M
ELABElevai Labs Inc
$ 0.0209
(-2.34%)
4.03M

ALZN Discussion

View Posts
Roozy Roozy 11 hours ago
Baloney via the Ault baloney mill
Cost us 1/4 of a mill
👍️0
TheFinalCD TheFinalCD 2 days ago
GM 20122
👍️0
tw0122 tw0122 2 days ago
“This is a major step towards potentially providing an important treatment innovation for the 43+ million Americans afflicted with Alzheimer’s, BD, MDD and PTSD. These results demonstrated the potential of AL001 to enhance brain-specific lithium delivery while minimizing systemic exposure in an Alzheimer’s disease mouse model, guiding development of enhanced lithium effectiveness and safety in human diseases,” said Stephan Jackman, Chief Executive Officer of Alzamend. “
👍️0
tw0122 tw0122 2 days ago
Mice lithium dementia Alzheimer's bipolar. Gets a little bump here. In some $1.39 low floater 2m
👍️0
Roozy Roozy 2 weeks ago
Junk
👍️0
Roozy Roozy 4 weeks ago
Dust in the wind
👍️0
Awl416 Awl416 1 month ago
Don’t blink
👍️0
Roozy Roozy 1 month ago
Headed sub $1.25 on the way to .99 then……
👍️0
Monksdream Monksdream 1 month ago
ALZN under $2
👍️0
Roozy Roozy 2 months ago
Every day
Ault sells snake oil
👍️0
Monksdream Monksdream 2 months ago
ALZN new 52 week low
👍️0
Monksdream Monksdream 2 months ago
ALZN new 52=week low
👍️0
Monksdream Monksdream 2 months ago
ALZN new 52+week low
👍️0
Roozy Roozy 2 months ago
Now!!!
👍️0
Roozy Roozy 3 months ago
Headed sub $2 then submerged in the Aulty swamp
👍️0
Monksdream Monksdream 3 months ago
ALZN under $3
👍️0
Roozy Roozy 3 months ago
Doomed-dead-over
SUCKERS don’t be!!
👍️0
Roozy Roozy 3 months ago
$3…..$3
Hahahaha
👍️0
Roozy Roozy 3 months ago
down .60!!
👍️0
Roozy Roozy 3 months ago
Timber suckers
👍️0
TIMGZ TIMGZ 3 months ago
WAS ALREADY TO $5 IN JUST FEW HOURS AFTER TOUCHING THE $15
👍️0
TheFinalCD TheFinalCD 3 months ago
3 to 15 back to 4 in one day🥴
👍️0
PennyStockTrader2 PennyStockTrader2 3 months ago
bought as low as 4.77 in the aftermarket. Will start selling somewhere in the $6 range if its hit, nothings guaranteed
👍️0
Roozy Roozy 3 months ago
Ah see the Ault kiss of death?
👍️0
PennyStockTrader2 PennyStockTrader2 3 months ago
well, finally finally we got some serious movement. Glad I bought all the way down to 2 bucks, it was painful, but I got used to the pain. I sold out 3/4 of my total position at various prices up to the top and started trading back in for a trading position. Raise a huge amount of cash. A number of these stocks go thru this craziness (BTTR, SXTP) where its algos doing all or most of the trading. At $8 I would be a buyer under that, and a seller over 10 bucks. What it does nobody I repeat nobody knows, you dont have to know, you just need to be alert, take profits, and buy back in at reasonable prices. Dont make it more complicated than that. I probably should have sold my entire position but heck, it just kept going, crazy really.
👍️0
Roozy Roozy 3 months ago
Won’t
👍️0
Roozy Roozy 3 months ago
Pump/dump in effect
👍️0
Roozy Roozy 3 months ago
History dictates Ault stock dies
👍️0
Helter Skelter Helter Skelter 3 months ago
$ALZN +638% @ HOD 15.06...in play for dip & bounce...

👍️0
Helter Skelter Helter Skelter 3 months ago
WTF? Same news? On closer look...

Pretty clever, seems to have worked. Rack 'em, lol...

$ALZN

👍️0
glenn1919 glenn1919 3 months ago
ALZN..................................https://stockcharts.com/h-sc/ui?s=ALZN&p=W&b=5&g=0&id=p86431144783
👍️0
Invest-in-America Invest-in-America 3 months ago
ALZN: INDEED!!! (Just wait until the proverbial SHIT-HITS-THE-FAN behind this SCAMMING-PR's company!!!)

MAKE THAT MONEY!!!
🎯 1 👍️ 1
Invest-in-America Invest-in-America 3 months ago
ALZN: IDENTICAL "news" --- biggest SCAM PR of the year!!! (Will be on "60-Minutes" shortly.)

MAKE THAT MONEY!!!
🎯 1 👍️ 1
TheFinalCD TheFinalCD 3 months ago
SAME NEWS???
Today 08:00AM
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder
(Business Wire)
+530.91%
Aug-12-24 08:00AM
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder
(Business Wire)
Aug-06-24 08:00AM
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder
(Business Wire)
-9.84%
05:32AM
Alzamend Neuro partners with Mass General for Alzheimers treatment trial
(Clinical Trials Arena)
🎯 1 👍️ 1
Awl416 Awl416 3 months ago
Don’t blink
👍️0
Awl416 Awl416 3 months ago
LOL
👍️0
TheFinalCD TheFinalCD 3 months ago
imagine this goes back to its IPO price

how sick would that be

$33 ipo
👍️0
TheFinalCD TheFinalCD 3 months ago
$12?
👍️0
Roozy Roozy 3 months ago
$33 ipo
👍️0
Roozy Roozy 3 months ago
Fraudulent
🎯 1 👍️ 1
TheFinalCD TheFinalCD 3 months ago
CONGRAT$ YOU DID IT AGAIN
👍️0
TheFinalCD TheFinalCD 3 months ago
WOW $6 ALZN who made $$$?
👍️0
TheFinalCD TheFinalCD 3 months ago
https://x.com/READY_2_PROFIT/status/1825510077047988504

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174944705
👍️0
Awl416 Awl416 3 months ago
7m volume
👍️0
Awl416 Awl416 3 months ago
Oh geez
👍️0
TheFinalCD TheFinalCD 3 months ago
Cmon
👍️0
Awl416 Awl416 3 months ago
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder
👍️0
TheFinalCD TheFinalCD 3 months ago
https://x.com/NuntioBot/status/1825503187408699862

https://finviz.com/quote.ashx?t=ALZN&p=d#google_vignette

IN 2.84
👍️0
Roozy Roozy 3 months ago
Bloviation
👍️0
Roozy Roozy 4 months ago
It has no value…
IPO @ $33
👍️0

Your Recent History

NASDAQ
ALZN
Alzamend Neuro
NASDAQ
AGNCL
AGNC Investment
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved